Table 2 Health care utilization and anti-hypertensive prescription at the end of follow-up (12 month).
Items | Usual Care (N = 184) | NRP (N = 190) | P value* |
|---|---|---|---|
Private hospitalization (%) | 0.493 | ||
0 | 177 (96.2) | 185 (96.4) | |
1 | 6 (3.3) | 3 (1.6) | |
>1 | 1 (0.5) | 2 (1.1) | |
Private clinic visit (%) | 0.192 | ||
0 | 86 (46.7) | 82 (43.2) | |
1–10 | 39 (21.2) | 31 (16.3) | |
>10 | 59 (32.1) | 77 (40.5) | |
GOPC visit (%) | 0.234 | ||
0–5 | 121 (65.8) | 139 (73.2) | |
6–10 | 57 (31.0) | 44 (23.2) | |
>10 | 6 (3.3) | 7 (3.7) | |
A&E visit (%) | 0.928 | ||
0 | 152 (82.6) | 158 (83.2) | |
1 | 27 (14.7) | 28 (14.7) | |
>1 | 5 (2.7) | 4 (2.1) | |
Public hospitalization %) | 0.582 | ||
0 | 157 (85.3) | 168 (88.4) | |
1 | 18 (9.8) | 12 (6.3) | |
2 | 5 (2.7) | 7 (3.7) | |
>2 | 4 (2.2) | 3 (1.6) | |
SOPD visit (%) | 0.797 | ||
0 | 117 (63.6) | 123 (64.7) | |
1 | 24 (13.0) | 29 (15.3) | |
2 | 19 (10.3) | 15 (7.9) | |
>2 | 24 (13.0) | 23 (12.1) | |
Type of anti-hypertensive (%) | 0.226 | ||
Reduce type of anti-hypertensive | 4 (2.2) | 2 (1.1) | |
No Change | 174 (94.6) | 186 (97.9) | |
Add a new anti-hypertensive | 6 (3.3) | 2 (1.1) | |
Change dosage (%) | 0.055 | ||
No changed | 162 (88) | 179 (94.2) | |
Changed | 22 (12) | 11 (5.8) |
